Clinical trials: Metabolic Evaluation
Mixed Dyslipidemia, Coronary Heart Disease
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with multiple abnormal lipid levels in the…
- Conditions
- Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
- Trial name
- NCT00300469
- Testing
- ABT-335, Atorvastatin
- Where
- United States
- Volunteers
- 613 people
- Sponsor
- Abbott
Diabetes Prevention
Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)
Safety and tolerability of a soy-protein Russian Tarragon complex versus a placebo.
- Trial name
- RT2 (NCT02088203)
- Testing
- Dose 1, Dose 2, Dose 0
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
This is a multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II trial of twelve weeks of KBP-042 administered as daily s.c.
- Trial name
- NCT03230786
- Where
- 30 sites in Czechia, Denmark and 4 more
- Volunteers
- 255 people
- Sponsor
- KeyBioscience AG
Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS
ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
A first-in-human study using ISP-001 in patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
- Trial name
- NCT05682144
- Testing
- Autologous Plasmablasts (B cells)
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Immusoft of CA, Inc.
Type 2 Diabetes Mellitus
Tofogliflozin GLP-1 Analogue Combination Trial
An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.
- Trial name
- NCT02537834
- Testing
- Tofogliflozin, GLP-1 analogue
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Kowa Company, Ltd.
Metabolism and Nutrition Disorder
Prospective Evaluation of the Incidence of PICS
Advances in modern medicine and critical care interventions have greatly impacted survival of critically ill patients, but these interventions are not without consequences.
- Trial name
- ProsPICS (NCT03584399)
- Testing
- PICS in critically ill pediatric population
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Indiana University
Obesity
Evaluation of Health Improvement in Obese Patients With Obesity-related Comorbidities Followed by EndoZip Procedure
multicenter, prospective, single arm study will include up to 45 patients, (up to 30 patients per site), aimed at evaluating the performance of the EndoZip System in obese patients with type 2 diabetes and / or hypertension who…
- Trial name
- CL00010 (NCT05623163)
- Testing
- EndoZip System
- Where
- 2 sites in Czechia, Italy
- Volunteers
- 38 people
- Sponsor
- Nitinotes Surgical Ltd.
Healthy, Hyperlipidemias
Effect of Goji Berry Consumption on Biochemical Parameters
Goji Berry as a functional food have been shown to reduce risk of hyperlipidemia, type 2 diabetes, etc. However, human studies are limited in this area.
- Trial name
- NCT06190587
- Testing
- Goji Berry
- Where
- Cyprus
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Eastern Mediterranean University
Obesity, Overweight
A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07881887
- Testing
- LY4167586
- Where
- 12 sites in United States, Singapore
- Volunteers
- 617 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.
The study is being conducted to evaluate the efficacy and safety of Noiiglutide Injection as mono-therapy with different doses in subjects with type 2 diabetes compared to placebo for 16 weeks.
- Trial name
- NCT03848793
- Testing
- HS-20004
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Asthma
Evaluation of Metabolic Profile of OC000459
An open label study in 9 male and 9 female healthy subjects to determine the pharmacokinetics of parent compound and metabolite after eight days of dosing.
- Trial name
- NCT02341521
- Testing
- OC000459
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Atopix Therapeutics, Ltd.
Mucopolysaccharidosis Type I (MPS I), Hurler Syndrome
RGX-111 Gene Therapy in Patients With MPS I
RGX-111 is a gene therapy which is intended to deliver a functional copy of the α-L-iduronidase (IDUA) gene to the central nervous system.
- Conditions
- Mucopolysaccharidosis Type I (MPS I), Hurler Syndrome, Hurler-Scheie Syndrome
- Trial name
- NCT03580083
- Testing
- RGX-111
- Where
- 2 sites in United States, Brazil
- Volunteers
- 21 people
- Sponsor
- REGENXBIO Inc.
Obesity
Self-Monitoring Assessment in Real Time
The purpose of the study is to test the effectiveness of two different methods of mobile dietary self-monitoring for weight loss.
- Trial name
- 2-SMART (NCT02868853)
- Testing
- Photo App, Diet App, Podcasts
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Hypercholesterolemia
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00080275
- Testing
- Niacin Extended-Release and simvastatin Tablets
- Volunteers
- 600 people
- Sponsor
- Kos Pharmaceuticals
Diabetes Mellitus, Kidney Disease
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)
This study aims to investigate whether new glucose-lowering medications, such as SGLT2 inhibitors (e.g., Forxiga/Jardiance) and GLP-1 receptor agonists (e.g., Ozempic), can reduce NETosis in diabetic patients, thereby mitigating…
- Trial name
- NETs (NCT06821919)
- Where
- Israel
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Western Galilee Hospital-Nahariya
Hyperphosphatemia, Kidney Disease
Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
Patients with end-stage renal disease (ESRD) commonly develop hyperphosphatemia due to the loss of excretory function of the kidney.
- Trial name
- NCT00660530
- Testing
- Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Illinois Chicago
Type 2 Diabetes, Dyslipidemia
Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study
Double-blind, randomized placebo-controlled study in type 2 diabetes and dyslipidemic patients.Patients will be randomized to one of four treatment arms for 16 weeks: placebo, fenofibrate, metformin, or metformin and fenofibrate…
- Trial name
- NCT00362765
- Testing
- Fenofibrate, Metformin
- Where
- 3 sites in Finland, Ireland and 1 more
- Volunteers
- 8 people
- Sponsor
- Solvay Pharmaceuticals
Cardiovascular Diseases, Hypertension
U-CHAMP: Urban Cardiovascular Health Assessment and Management Program
High blood pressure, elevated blood glucose and high cholesterol are related to the increased risk of stroke and heart disease. Many studies have shown that this risk can be significantly reduced by lowering blood pressure, blood…
- Conditions
- Cardiovascular Diseases, Hypertension, Hyperlipidemia, Hyperglycemia
- Trial name
- U-CHAMP (NCT00626041)
- Testing
- participant referral to primary care network physician
- Where
- 2 sites in Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Fanconi Anemia Complementation Group A, Fanconi Anemia
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
This is a long-term safety and efficacy follow-up study for subjects with Fanconi Anaemia Subtype A who have been treated with ex vivo gene therapy on the FANCOLEN-I trial.
- Trial name
- NCT04437771
- Testing
- Safety and efficacy assessments
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- Rocket Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.